@article{3020552,
    title = "The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema",
    author = "Chatziralli, I. and Papadakou, P. and Dimitriou, E. and Kazantzis, D. and Kapsis, P. and Theodossiadis, G. and Papathanassiou, M. and Theodossiadis, P.",
    journal = "Cutaneous and Ocular Toxicology (formerly Journal of Toxicology - Cutaneous and Ocular Toxicology)",
    year = "2021",
    volume = "40",
    number = "2",
    pages = "66-69",
    publisher = "Taylor and Francis Ltd.",
    issn = "1556-9527, 1556-9535",
    doi = "10.1080/15569527.2021.1887886",
    keywords = "aflibercept;  hemoglobin A1c;  ranibizumab;  aflibercept;  angiogenesis inhibitor;  fusion protein;  ranibizumab;  vasculotropin;  vasculotropin receptor, adult;  Article;  best corrected visual acuity;  cell density;  cell size;  central corneal thickness;  central retinal thickness;  clinical article;  comorbidity;  controlled study;  cornea endothelium;  diabetic macular edema;  engineering;  female;  fluorescence angiography;  follow up;  human;  intraocular pressure;  loading drug dose;  male;  middle aged;  optical coherence tomography;  prospective study;  slit lamp microscopy;  spectral domain optical coherence tomography;  specular microscopy;  aged;  clinical trial;  cornea endothelium;  diabetic complication;  drug effect;  intravitreal drug administration;  macular edema;  visual acuity, Aged;  Angiogenesis Inhibitors;  Diabetes Complications;  Endothelium, Corneal;  Female;  Humans;  Intravitreal Injections;  Macular Edema;  Male;  Middle Aged;  Ranibizumab;  Receptors, Vascular Endothelial Growth Factor;  Recombinant Fusion Proteins;  Tomography, Optical Coherence;  Vascular Endothelial Growth Factors;  Visual Acuity",
    abstract = "Purpose: To evaluate the characteristics of corneal parameters in patients with diabetic macular oedema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: Participants in this study were 36 patients with DME, treated with either intravitreal ranibizumab (n = 16) or aflibercept (n = 20). All participants underwent best-corrected visual acuity (BCVA) measurement, optical coherence tomography and non-contact specular microscopy to evaluate corneal endothelium parameters (endothelial cell density-ECD, hexagonality, coefficient of variation of the cell size and central corneal thickness-CCT), at baseline and at months 6 and 12 after the first intravitreal injection. Comparisons between baseline and months 6 and 12 were performed. Results: There was no statistically significant difference regarding ECD, hexagonality, coefficient of variation of the cell size and CCT at month 6 and 12 post initial injection compared to baseline in patients with DME. BCVA improved significantly at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Central retinal thickness was significantly reduced at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Conclusion: Intravitreal anti-VEGF injections in patients with DME were found not to affect corneal parameters, namely ECD, hexagonality, coefficient of variation of the cell size and CCT at the long-term follow-up of 12 months. © 2021 Informa UK Limited, trading as Taylor & Francis Group."
}